Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

11.16 +0.38 (+3.53%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 20, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 19, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

CCXI INVESTOR NEWS: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – CCXI

May 18, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

May 17, 2021

From Law Offices of Howard G. Smith

Via Business Wire

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline

May 17, 2021

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)

May 13, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

Lost Money in ChemoCentryx, Inc.?

May 12, 2021

From Gibbs Law Group

Via Business Wire

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 12, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline

May 11, 2021

From Scott+Scott Attorneys at Law LLP

Via Business Wire

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces ChemoCentryx, Inc. (CCXI) Sued for Misleading Investors

May 11, 2021

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders

Via EIN Presswire

Topics Lawsuit

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

May 10, 2021

From Glancy Prongay & Murray LLP

Via Business Wire

40 Stocks Moving In Monday's Mid-Day Session ↗

May 10, 2021

Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news. Obalon Therapeutics, Inc. (NASDAQ: OBLN) gained 35% to $2.97. Cue...

Via Benzinga

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

May 10, 2021

From Law Offices of Howard G. Smith

Via Business Wire

Notice of Lead Plaintiff Deadline for Shareholders in the ChemoCentryx, Inc. Class Action Lawsuit

May 10, 2021

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

May 07, 2021

From The Law Offices of Frank R. Cruz

Via Business Wire

70 Biggest Movers From Friday ↗

May 10, 2021

Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1...

Via Benzinga

SHAREHOLDER ALERT: Robbins LLP Announces That ChemoCentryx, Inc. (CCXI) is Being Sued for Misleading Shareholders

May 07, 2021

From Robbins LLP

Via Business Wire

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc.

May 07, 2021

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop ↗

May 07, 2021

Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81. The U.S. has the...

Via Benzinga

Topics Stocks

Stocks Reverse Course, Investors Look at Flip Side of Economic Data ↗

May 07, 2021

While a lackluster April jobs report initially sunk stocks this morning, the indexes are bouncing back as investors speculate that the disappointing data could mean the continuation of easy policies...

Via Talk Markets

Topics Economy

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 07, 2021

Gainers Yield10 Bioscience (NASDAQ:YTEN) stock increased by 20.74% to $10.36 during Friday's regular session. As of 12:30 EST, Yield10 Bioscience's stock is...

Via Benzinga

Why ChemoCentryx Stock Is Cratering Again Today ↗

May 07, 2021

Investors aren't optimistic after an FDA advisory committee vote for avacopan.

Via The Motley Fool

Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide ↗

May 07, 2021

Midway through trading Friday, the Dow traded up 0.45% to 34,705.48 while the NASDAQ rose 1.35% to 13,816.46. The S&P also rose, gaining 0.77% to 4,233.93. The U.S. has the...

Via Benzinga

Topics Stocks

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

May 07, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Why ChemoCentryx Shares Are Plunging Today ↗

May 07, 2021

ChemoCentryx (NASDAQ: CCXI) shares are trading lower following a vote from the FDA panel on whether the efficacy data support approval on its Avacopan in ANCA-Associated...

Via Benzinga

56 Stocks Moving In Friday's Mid-Day Session ↗

May 07, 2021

Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday....

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April ↗

May 07, 2021

Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68. The U.S. has...

Via Benzinga

Topics Stocks

Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges ↗

May 07, 2021

Yesterday, the FDA’s Arthritis Advisory Committee panelists went through cloudy data while complaining about the design of the Phase 3 trial for ChemoCentryx Inc...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.